Data mustnt sit still. It is imperative that information can be exchanged within machines, between machines and from machines to systems where it is secure in order for researchers to read their data. To improve connectivity and enable efficient and secure exchange of data, Thermo Fisher Scientific now offers the CryoMed Controlled-Rate Freezer with Open Platform Communications Unified Architecture (OPC UA) functionality.
Technology Networks had the pleasure of talking to Wilfredo Marn, senior product application specialist from Thermo Fisher Scientific, to learn more about OPC UA and how it is suited to biobanking and cell and gene therapy development. In this interview, Wilfredo also highlights the benefits of incorporating OPC UA into the CryoMed Controlled-Rate Freezer, and the importance of OPC UA functionality in the lab of the future.
Zoe Braybrook (ZB): Can you briefly describe what OPC UA is and the benefits it offers?
Wilfredo Marn (WM): Sure, OPC UA stands for Open Platform Communications Unified Architecture allowing for information exchange in a standardized manner. This means that it is a well-organized and defined protocol allowing for interoperability of instruments. The benefits include flexibility to work across operating system platforms, data security and scalability as the data is transformed into information. In industrial settings, OPC UA offers end-users the building blocks to fit into their control system workflows.
ZB: OPC UA has already been successfully integrated into other industries including food and beverage as well as energy and utilities, could you perhaps discuss how you think its suited to biobanking and those producing cell and gene therapies?
WM: It certainly has been integrated in many other industries as they can make better and faster business decisions using insights from the accessible information. That is the key to OPC UA, as it follows industry advised companion specifications to provide contextualized data in a process system. For biobankers, it helps support the sample traceability, standardization and documentation process that is sought for collaboration. As these researchers look to modernize their facilities and potentially grow operations within a building information management system, OPC UA functionality in their equipment offers similar advantages as having biomaterial with associated clinical data.
For cell and gene therapy production facilities, cryopreservation is a vital step to maintain the integrity of cells being modified, stored or distributed. Having a controlled-rate freezer with OPC UA integrates nicely as a server to communicate with several types of client programs they currently utilize.
ZB: Why did Thermo Fisher Scientific choose to incorporate this function into the CryoMed Controlled-Rate Freezer in particular?
WM: Thermo Fisher Scientific is continually at the forefront of innovation that enables our customers to succeed. The investment into research and development is tremendous and our same customers provided valuable feedback to support how we implemented OPC UA as the previous updated model was being launched. As a former end-user, the CryoMed Controlled-Rate Freezer was a great choice to update as an instrument that is necessary for several important research and production workflows. Cryopreservation of biomaterial is performed at several points, so it was vital to maintain the precision performance and reliability that the CryoMed is known to deliver.
ZB: How does CryoMed provide researchers with modern connectivity but also ensure their data remains safe?
WM: The CryoMed has several options to connect in a research setting including wireless remote monitoring, PC-connected remote control and now OPC UA functionality. It was also one of the first cryopreservation products to meet 21 CRF Part 11 requirements by the FDA for electronic records. On the new user-interface, as a starting point, the updated firmware asks for unique usernames with passwords, defines user roles and retains audit and event logs. Taking a step further, OPC UA also has security built into its protocol for access control, authentication and encryption. So, in a control system, there will always be rules between different levels to connect, find and read data as information.
ZB: What factors should labs wanting to improve their processes consider with regard to OPC UA adoption? How easy is it for labs looking to improve their processes to adopt OPC UA products?
WM: One factor that we continue to highlight is that OPC UA communication has been well-supported and industry-approved over several years. The Unified Architecture has evolved as a successor of classic OPC with emphasis on platform independence, security and integration. Therefore, a product with OPC UA like the CryoMed can be easily deployed to enhance efficiency of their process. For laboratories, a real advantage applies when looking to scale for production requiring GMP. It can turn a very manual method into closely documented automatic outputs between multiple machines as it orchestrates data. OPC UA can be easily adopted but requires the same future mindset we attribute to biosamples having the potential for discovery or therapies.
ZB: How important will OPC UA functionality be in the lab of the future?
WM: With the fast-moving pace of technology and associated expenses, labs are looking to future-proof by incorporating sustainable planning into their operations. Were thinking ahead to how various instruments in the same workflow can communicate and support manufacturing with OPC UA as a framework in the industrial internet of things. Through these efforts, there will be more products developed that utilize OPC UA making it easier to exchange the compliant and contextualized data, thus maintaining high-quality at lower costs. Altogether, the lab of future will be able to use information from these physical machines for predictive analytics by modeling data to provide several paths for success.
Wilfredo Marn was speaking to Zoe Braybrook, Marketing Campaign Coordinator for Technology Networks.
See the article here:
OPC UA for Sample Process Automation Improving Data Harmonization for Biobanks and Cell and Gene Therapies - Technology Networks
- Dosing paused in Pfizer DMD gene therapy trial after patient death - Muscular Dystrophy News - May 14th, 2024
- Astellas CEO Q&A (Part 1): There Is No Playbook on Cell and Gene Therapies - MedCity News - May 14th, 2024
- Bluebird: Cells collected from 1st sickle cell patient having... - Sickle Cell Disease News - May 14th, 2024
- Regeneron Gene Therapy Reaches New Heights In Restoring Hearing - Scrip - May 14th, 2024
- Young participant in Pfizer's DMD gene therapy trial dies - Fierce Biotech - May 14th, 2024
- Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trial - Genetic Engineering & Biotechnology News - May 14th, 2024
- Gene therapy trials treat inherited blindness and deafness - DW (English) - May 14th, 2024
- Deaf girl is cured in world first gene therapy trial - The Independent - May 14th, 2024
- beyond-the-lab-cell-and-gene-therapy - Drug Target Review - May 14th, 2024
- Child who was born deaf can now hear whispers and parents clapping for first time thanks to 'mind-blowing' gene therapy - New York Post - May 14th, 2024
- White Paper: Navigating the regulatory path of CRISPR-based therapeutics 13 May 2024 - SelectScience - May 14th, 2024
- Krystal Biotech touts topical gene therapy uptake, plots overseas launches - FiercePharma - May 14th, 2024
- Pharming uproots angioedema gene therapy collab with Orchard - Fierce Biotech - May 14th, 2024
- Deaf toddler playing piano and dancing after world-first gene therapy - The Telegraph - May 14th, 2024
- New gene therapy allows deaf child to hear DW 05/09/2024 - DW (English) - May 14th, 2024
- Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines - BioSpace - May 14th, 2024
- Gene therapy provision would make life-saving treatment more accessible and equitable - Star Tribune - May 14th, 2024
- British girl's hearing restored in pioneering gene therapy trial - Sky News - May 14th, 2024
- ASGCT24: Translational Research Powering Potentially Transformative Therapies - BioSpace - May 14th, 2024
- Advancing Delivery of AAV Vector-Based Gene Therapies Using Bispecific Antibodies (ASGCT 2024) - BioPharm International - May 14th, 2024
- Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results - Yahoo Finance - February 27th, 2024
- New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle - CNBC - February 27th, 2024
- 10 gene therapy companies you should know about - Labiotech.eu - February 27th, 2024
- Former Penn employee sues Gene Therapy Program director, alleging 'unethical and illegal conduct' - The Daily Pennsylvanian - February 27th, 2024
- Gene therapy can't cure deafness because it doesn't need to be cured - The Philadelphia Inquirer - February 27th, 2024
- Fetal surgery expert Tippi MacKenzie shifts to in-utero gene therapy - STAT - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- CU Anschutz Set to Launch Gene Therapy Trials for Heart Disorder - University of Colorado Anschutz Medical Campus - February 27th, 2024
- ICH targets cell and gene therapies, real-world data as topics ripe for harmonization - Regulatory Focus - February 27th, 2024
- Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 - Business Wire - February 27th, 2024
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in ... - GlobeNewswire - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - The Bakersfield Californian - February 27th, 2024
- Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff - STAT - February 27th, 2024
- Ed Silverman on new gene therapies, biosimilars, coffee, and more - STAT - STAT - February 27th, 2024
- Combatting HIV using gene therapy - Drug Target Review - February 27th, 2024
- NCDHHS working with federal government on increasing access to sickle cell disease treatment - WECT - February 27th, 2024
- Cell Therapy Weekly: FDA Approves First Cell Therapy For Solid Tumors - RegMedNet - February 27th, 2024
- Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age ... - Business Wire - February 27th, 2024
- New sickle cell therapy uses gene editing at MUSC | Health | postandcourier.com - The Post and Courier - February 27th, 2024
- Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency - Nature.com - February 18th, 2024
- Gene therapy, blood transfusions, stool monitoring: The Sydneysiders trying to escape death - Sydney Morning Herald - February 18th, 2024
- Not too late to repair: gene therapy improves advanced heart failure in animal model - Baylor College of Medicine | BCM - February 18th, 2024
- Direct Administration of CRISPR-Cas9: Tools for Cell and Gene Therapy - Forbes - February 18th, 2024
- Gene therapy's promise seen in its success for AADC deficiency - AADC News - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment - Diagnostic and Interventional Cardiology - February 18th, 2024
- FDA to review expanded use of Sarepta Duchenne gene therapy - Yahoo Finance - February 18th, 2024
- How gene therapy can help treat a rare blood disorder - KUTV 2News - February 18th, 2024
- CRISPR gene therapy Casgevy secures approval in Europe - Pharmaceutical Technology - February 18th, 2024
- FDA Updates for the Week of Feb. 12, 2024: New Approvals, an Extended Review and Goal Dates Set - Managed Healthcare Executive - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure - Business Wire - February 18th, 2024
- Lisa Jarvis: A cure for some kinds of hearing loss? Gene therapies are getting closer - St. Paul Pioneer Press - February 18th, 2024
- Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of ... - Yahoo Finance - February 18th, 2024
- Crispr Therapeutics' Gene Therapy Wins EU Approval - TipRanks.com - TipRanks - February 18th, 2024
- Revolutionizing Gene Therapy: A Novel Technique for In Vivo CAR T Cells - Medriva - February 18th, 2024
- How Stella Vnook is 'infusing innovation' into cell therapies with Likarda's technology - BioPharma-Reporter.com - February 18th, 2024
- Using cancer's 'superpower' to boost T-cell therapies in mice - FierceBiotech - February 18th, 2024
- Parkinson's Disease Patient Identification and Education Will Need to Improve When New Disease Modifying ... - Yahoo Finance - February 18th, 2024
- CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance - February 18th, 2024
- Gene Therapy: A Ray of Hope for Heart Failure Treatment | Health News - Medriva - February 18th, 2024
- Gene therapy trials restore hearing to children born deaf - The Hill - February 2nd, 2024
- Early Trial Success for Inherited Deafness Gene-Therapy - RegMedNet - February 2nd, 2024
- Sickle cell gene therapy first focus of Medicaid pay model - Modern Healthcare - February 2nd, 2024
- Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer - BioPharma-Reporter.com - February 2nd, 2024
- Angiodema: Gene therapy blocks painful hereditary disorder - BBC - February 2nd, 2024
- FDA: Genome editing therapies may use accelerated approval pathway - Regulatory Focus - February 2nd, 2024
- CRISPR tech treats severe hereditary condition successfully - Interesting Engineering - February 2nd, 2024
- Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness - Technology Networks - February 2nd, 2024
- Gene-based therapy may slow development of life-threatening heart condition - Medical Xpress - February 2nd, 2024
- Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum ... - Business Wire - February 2nd, 2024
- Replacing the PKP2 gene prolongs survival in ARVC patients - Drug Target Review - February 2nd, 2024
- Cell and gene therapies top pharmaceutical industry trend to watch for 2024 - Pharmaceutical Technology - February 2nd, 2024
- Gene Therapy Restores Hearing in Children with Hereditary Deafness - The Hearing Review - February 2nd, 2024
- 2 Dutch among 10 "functionally cured" of hereditary swelling disease by new gene therapy - NL Times - February 2nd, 2024
- FDA publishes final industry guidance for CAR-T and gene therapies - PMLiVE - February 2nd, 2024
- Gene therapy cures hereditary deafness in two people - Advanced Science News - February 2nd, 2024
- Hearing Restored in Deaf Children in Gene Therapy Clinical Trial - Securities.io - February 2nd, 2024
- Vivet Therapeutics Receive 4.9 Million to Advance Development of Gene Therapy - European Pharmaceutical Manufacturer - February 2nd, 2024
- Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on ... - GlobeNewswire - February 2nd, 2024
- Allogene parks Notch CARs, leaving one on the road - FierceBiotech - February 2nd, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - The Associated Press - January 25th, 2024